retatrutide type 2 diabetes phase 2 trial hba1c Effects of retatrutide, dulaglutide, and placebo on gastric emptying in Medscape | The investigational triple

I'm thankful that is what I did

doi:10.1016/j.beem.2009.03.006

Similar combinations of active biological agents might minimise the unwanted cardiovascular effects of traditional small-molecule-based drugs or target anti-inflammatory pharmacology to only certain select tissues

Imbriani P, Martella G, Bonsi P, Pisani A (2022) Oxidative stress and synaptic dysfunction in rodent models of Parkinsons disease

The American Diabetes Association Standards of Care do not include berberine in evidence-based treatment algorithms, and patients with type 2 diabetes should not discontinue prescribed medications in favor of supplements without medical supervision

Medically reviewed by Tarun Kumar, Prescribing Pharmacist (GPhC 2233073) Last reviewed: 25 June 2026 Quick Summary Retatrutide is a triple incretin receptor agonist being studied as a once-weekly injectable treatment for obesity